TRIM21 has been shown to stabilise or degrade IRFs, suggesting a regulatory role in maintaining IFN signalling balance and preventing exaggerated type I IFN response.[11,12] Furthermore, activation of type I IFN system in pSS patients is associated with the presence of anti-Ro autoantibody. The gene discussed is IFNA1; the disease is peeling skin syndrome.